Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIENCE trial of allogeneic adipose-derived stem cells for ischemic heart failure
NL-OMON47824Phase 3Recruiting
- Sponsor
- Rigshospitalet
- Start
- Apr 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Ischemic congestive heart failure (ICM-HF), coronary arteriosclerosis and heart failure (HF) comparing CSCC_ASC treatment with Placebo control (2 arms). Started Apr 2017; status: recruiting.
02
Drugs
CSCC_ASC
03
Conditions
Ischemic congestive heart failure (ICM-HF)coronary arteriosclerosisheart failure (HF)
Beyond the preview
Go deeper on NL-OMON47824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47824.